Drugs News and Research

RSS

LSUHSC: Differences in drug metabolism can lead to differences in the effectiveness of candidate drug

Research led by Wayne L. Backes, PhD, Professor of Pharmacology and Associate Dean for Research at LSU Health Sciences Center New Orleans School of Medicine, has found that drug metabolism depends not only upon which enzymes are present in an individual, but also how they interact, and that can be the difference in whether a drug is safely eliminated from the body or is converted into a toxic or carcinogenic byproduct.

18 Mar 2010

MediCare International offers insurance for all nationalities

The Lebanon is an important centre for international workers - Post conflict international health cover hard to arrange - Good hospital facilities can only be accessed with the right cover - MediCare International offers insurance for all nationalities

18 Mar 2010

McGill researchers pioneer major breakthrough in DNA nanotechnology

A team of McGill Chemistry Department researchers led by Dr. Hanadi Sleiman has achieved a major breakthrough in the development of nanotubes - tiny "magic bullets" that could one day deliver drugs to specific diseased cells.

18 Mar 2010

SANTE study: Deep brain stimulation can reduce seizures

A recent study organized by Stanford University researchers found patients with refractory partial and secondarily generalized seizures had a reduction in seizures after deep brain stimulation. This multi-center clinical trial determined that the benefits of stimulation of the anterior nuclei of thalamus for epilepsy (SANTE) persisted and by 2 years there was a 56% reduction in seizure frequency.

18 Mar 2010

Acurox NDA: FDA schedules Advisory Committee meeting

Acura Pharmaceuticals, Inc. and King Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration ("FDA") has publically announced the scheduling of an April 22, 2010 Advisory Committee meeting to discuss the New Drug Application ("NDA") for Acurox® (oxycodone HCl and niacin) Tablets and the results of studies evaluating the addition of niacin for the purpose of reducing the misuse of oxycodone.

18 Mar 2010

Feelings of guilt and shame haunt mothers with eating difficulties

They would love to be perfect mothers. Instead, they feel ashamed and inadequate, and fearful that their children might inherit their eating difficulties.

18 Mar 2010

Cryotherapy may become the future treatment for cancer

Cryotherapy, an interventional radiology treatment to freeze cancer tumors, may become the treatment of the future for cancer that has metastasized in soft tissues (such as ovarian cancer) and in bone tumors.

18 Mar 2010

New specialty service at Montefiore Medical Center helps patients with drug allergies

A Westchester patient takes aspirin for pain, but develops rashes and hives. A Bronx patient with a gastrointestinal problem caused by bacteria is prescribed penicillin, then passes out. A Bronx woman is given a contrast dye for an internal diagnostic exam, then her skin peels off.

18 Mar 2010

NICE leaves many patients with rarer forms of cancer without drugs

The National Institute for Health and Clinical Excellence (NICE) is failing to follow its own guidance aimed at making live-extending treatments available on the NHS, leaving many patients with rarer forms of cancer without drugs that could prolong their lives, a campaign group has said.

18 Mar 2010

Drug makers convene to discuss new strategies on how to improve patient care and reduce healthcare costs

Executives from pharmaceutical companies and health care payer and provider organizations convened at the "Selling Pharmaceuticals in 2015" forum in Philadelphia to discuss mutually beneficial partnerships that, if implemented, could replace the traditional model of selling drugs on price, features and benefits with a new model that focuses on quantifying and communicating total value.

18 Mar 2010

Drugmakers are 'under-exposed' in emerging markets, report says

Growing markets for pharmaceuticals in China, Brazil, Russia and India are outpacing national markets in Europe and the U.S., but major drugmakers have been slow to expand in these markets and may lose opportunities, a new study finds, The New York Times reports. To put the shift in perspective, China will overtake both France and Germany next year in terms of drug spending, while Brazil will overtake Britain, according to the report by research firm IMS Health.

18 Mar 2010

Agendia to participate in groundbreaking clinical trial for breast cancer

Agendia, a world leader in molecular cancer diagnostics, announced today it will participate in the highly anticipated I-SPY 2 TRIAL for breast cancer, set to launch at the first of nearly twenty research sites.

18 Mar 2010

Democrats take aim at deficit targets, continue to wait for CBO numbers on health overhaul

"With Congress just days away from an expected vote, Democrats still hadn't settled on final language of the bill and until they do the Congressional Budget Office can't release an estimate for how much the complete package would cost." House Majority Leader Steny Hoyer (D., Md.) said yesterday that "he hoped Democratic leaders would be able to lock down final details soon.

18 Mar 2010

I-SPY 2: The Biomarkers Consortium launches clinical trial for high risk, fast-growing breast cancers

The Biomarkers Consortium, a unique public-private partnership that includes the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and major pharmaceutical companies, led by the Foundation for the National Institutes of Health (FNIH), today announced the launch of a highly anticipated clinical trial to help screen promising new drugs being developed for women with high risk, fast-growing breast cancers—women for whom an improvement over standard treatment could dramatically change the odds of survival.

18 Mar 2010

CytoDyn commences full humanization of Cytolin immune therapy for treating HIV/AIDS

CytoDyn, Inc. has begun full humanization of Cytolin®, the Company’s unique immune therapy for treating HIV/AIDS. Although a murine (mouse) version of Cytolin® was used for previous human experience that included some 200 patients successfully treated for up to two years, as well as an encouraging Phase I(b)/II(a) study, the Company believes that a fully-humanized version is necessary for the clinical trial that is expected to follow the current one (described at http://clinicaltrials.gov) for the reasons explained below.

17 Mar 2010

Zogenix announces the initiation of pivotal Phase 3 clinical trial with ZX002

Zogenix, Inc., a privately held pharmaceutical company, announced that it has initiated a pivotal Phase 3 clinical trial with ZX002, a novel, oral, controlled-release formulation of hydrocodone without acetaminophen. ZX002 is being developed for the treatment of moderate to severe pain in individuals who require around-the-clock opioid therapy for the control of pain.

17 Mar 2010

Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced that they have received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACU-4429, an investigational oral treatment for dry age-related macular degeneration (dry AMD).

17 Mar 2010

CNS Network purchases Logos Technologies' pro-active EDC system for streamlining clinical trials

It is announced today that CNS Network has purchased ALPHADAS®, Logos Technologies Inc’s early phase, e-source data capture system and site automation tools to accelerate and streamline its clinical trials. ALPHADAS is to be implemented in their Orange County Research Center, California, USA.

17 Mar 2010

ALS TDI, Aestus Therapeutics to test potential small-molecule compounds to stop progression of ALS

The ALS Therapy Development Institute and Aestus Therapeutics, Inc., announced their plans today to test several potential small-molecule compounds to slow or stop the progression of Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease).

17 Mar 2010

Meridian Bioscience revises fiscal 2010 guidance, expects net sales between $145M and $153M

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it is revising downward its previous sales and earnings guidance for the fiscal year ending September 30, 2010. This action is being taken as a result of weaker than expected operating results for the second quarter ending March 31, 2010, based on preliminary results to date. Separately, Meridian announced that it will file a 510(k) for FDA marketing clearance next week in connection with its illumigene™ C. difficile product.

17 Mar 2010

Drugs News and Research

LSUHSC: Differences in drug metabolism can lead to differences in the effectiveness of candidate drug

MediCare International offers insurance for all nationalities

McGill researchers pioneer major breakthrough in DNA nanotechnology

SANTE study: Deep brain stimulation can reduce seizures

Acurox NDA: FDA schedules Advisory Committee meeting

Feelings of guilt and shame haunt mothers with eating difficulties

Cryotherapy may become the future treatment for cancer

New specialty service at Montefiore Medical Center helps patients with drug allergies

NICE leaves many patients with rarer forms of cancer without drugs

Drug makers convene to discuss new strategies on how to improve patient care and reduce healthcare costs

Drugmakers are 'under-exposed' in emerging markets, report says

Agendia to participate in groundbreaking clinical trial for breast cancer

Democrats take aim at deficit targets, continue to wait for CBO numbers on health overhaul

I-SPY 2: The Biomarkers Consortium launches clinical trial for high risk, fast-growing breast cancers

CytoDyn commences full humanization of Cytolin immune therapy for treating HIV/AIDS

Zogenix announces the initiation of pivotal Phase 3 clinical trial with ZX002

Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD

CNS Network purchases Logos Technologies' pro-active EDC system for streamlining clinical trials

ALS TDI, Aestus Therapeutics to test potential small-molecule compounds to stop progression of ALS

Meridian Bioscience revises fiscal 2010 guidance, expects net sales between $145M and $153M

Drug Discovery - Second Edition eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News